Survival of cancer patients with pre-existing heart disease.
cancer
pre-existing cardiovascular disease
survival
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
03 Aug 2022
03 Aug 2022
Historique:
received:
28
04
2022
accepted:
27
07
2022
entrez:
3
8
2022
pubmed:
4
8
2022
medline:
6
8
2022
Statut:
epublish
Résumé
While cancer outcomes have improved over time, in Northern Ireland they continue to lag behind those of many other developed economies. The role of comorbid conditions has been suggested as a potential contributory factor in this but issues of data comparability across jurisdictions has inhibited efforts to explore relationships. We use data from a single jurisdiction of the UK using data from - the Northern Ireland Cancer Registry (NICR), to examine the association between mortality (all-cause and cancer specific) and pre-existing cardiovascular diseases among patients with cancer. All patients diagnosed with cancer (excluding non-melanoma skin cancer) between 2011 and 2014 were identified from Registry records. Those with a pre-existing diagnosis of cardiovascular diseases were identified by record linkage with patient hospital discharge data using ICD10 codes. Survival following diagnosis was examined using descriptive statistics and Cox proportional hazards regression analyses. Analyses examined all-cause mortality and cancer specific mortality for lung, colorectal, breast and prostate cancer. As well as cardiovascular diseases, regression models controlled for age, gender (where appropriate), deprivation (as quintiles), stage at diagnosis and other comorbidities. Almost 35,000 incident cancer cases were diagnosed during the study period of which approximately 23% had a prior heart condition. The pan-cancer hazard ratio for death in the presence of pre-existing cardiovascular diseases was 1.28 (95% CI: 1.18-1.40). All-cause and cancer specific mortality was higher for patients with cardiovascular diseases across lung, female breast, prostate and colorectal cancer groups after controlling for age, gender (where appropriate), deprivation (as quintiles), stage at diagnosis and other comorbidities. Pre-existing morbidity may restrict the treatment of cancer for many patients. In this cohort, cancer patients with pre-existing cardiovascular diseases had poorer outcomes than those without cardiovascular diseases. A high prevalence of cardiovascular diseases may contribute to poorer cancer outcomes at a national level.
Sections du résumé
BACKGROUND
BACKGROUND
While cancer outcomes have improved over time, in Northern Ireland they continue to lag behind those of many other developed economies. The role of comorbid conditions has been suggested as a potential contributory factor in this but issues of data comparability across jurisdictions has inhibited efforts to explore relationships. We use data from a single jurisdiction of the UK using data from - the Northern Ireland Cancer Registry (NICR), to examine the association between mortality (all-cause and cancer specific) and pre-existing cardiovascular diseases among patients with cancer.
MATERIALS AND METHODS
METHODS
All patients diagnosed with cancer (excluding non-melanoma skin cancer) between 2011 and 2014 were identified from Registry records. Those with a pre-existing diagnosis of cardiovascular diseases were identified by record linkage with patient hospital discharge data using ICD10 codes. Survival following diagnosis was examined using descriptive statistics and Cox proportional hazards regression analyses. Analyses examined all-cause mortality and cancer specific mortality for lung, colorectal, breast and prostate cancer. As well as cardiovascular diseases, regression models controlled for age, gender (where appropriate), deprivation (as quintiles), stage at diagnosis and other comorbidities.
RESULTS
RESULTS
Almost 35,000 incident cancer cases were diagnosed during the study period of which approximately 23% had a prior heart condition. The pan-cancer hazard ratio for death in the presence of pre-existing cardiovascular diseases was 1.28 (95% CI: 1.18-1.40). All-cause and cancer specific mortality was higher for patients with cardiovascular diseases across lung, female breast, prostate and colorectal cancer groups after controlling for age, gender (where appropriate), deprivation (as quintiles), stage at diagnosis and other comorbidities.
CONCLUSION
CONCLUSIONS
Pre-existing morbidity may restrict the treatment of cancer for many patients. In this cohort, cancer patients with pre-existing cardiovascular diseases had poorer outcomes than those without cardiovascular diseases. A high prevalence of cardiovascular diseases may contribute to poorer cancer outcomes at a national level.
Identifiants
pubmed: 35922767
doi: 10.1186/s12885-022-09944-z
pii: 10.1186/s12885-022-09944-z
pmc: PMC9351236
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
847Informations de copyright
© 2022. The Author(s).
Références
J Clin Oncol. 2012 Jan 10;30(2):142-50
pubmed: 22147735
J Clin Oncol. 2008 Jan 1;26(1):54-9
pubmed: 18165640
Cancer Epidemiol Biomarkers Prev. 2015 Oct;24(10):1495-506
pubmed: 26359465
Clin Epidemiol. 2013 Nov 01;5(Suppl 1):3-29
pubmed: 24227920
Am J Mens Health. 2018 Nov;12(6):1807-1823
pubmed: 30203706
JACC CardioOncol. 2019 Sep 24;1(1):114-116
pubmed: 34396168
Thorax. 2018 Apr;73(4):339-349
pubmed: 29079609
Lancet. 2019 Sep 21;394(10203):1041-1054
pubmed: 31443926
Med Care. 1998 Jan;36(1):8-27
pubmed: 9431328
BMJ Open. 2013 Dec 03;3(12):e004074
pubmed: 24302511
Dis Colon Rectum. 2009 Jan;52(1):71-8
pubmed: 19273959
Thorax. 2006 Mar;61(3):232-9
pubmed: 16284219
J Natl Cancer Inst. 2002 Apr 3;94(7):490-6
pubmed: 11929949
Eur J Heart Fail. 2018 Dec;20(12):1721-1731
pubmed: 30191649
Eur J Cancer. 2001 Sep;37(13):1659-67
pubmed: 11527693
Int J Cardiol. 2020 Oct 15;317:167-173
pubmed: 32360647
BMJ. 2011 Jun 09;342:d3399
pubmed: 21659366
Cardiooncology. 2015 Nov 26;1(1):2
pubmed: 33530142
Thorax. 2013 Jun;68(6):551-64
pubmed: 23399908
J Clin Oncol. 2010 Jul 10;28(20):3307-15
pubmed: 20530272
Br J Cancer. 2011 Jun 28;105(1):170-6
pubmed: 21559016
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Adv Radiat Oncol. 2018 May 04;3(3):221-229
pubmed: 30202793
JACC CardioOncol. 2019 Jun 15;1(1):131-132
pubmed: 34396170
Br J Cancer. 2004 Jun 14;90(12):2332-7
pubmed: 15162155
Crit Rev Oncol Hematol. 2005 Sep;55(3):231-40
pubmed: 15979890
JACC CardioOncol. 2019 Dec 17;1(2):256-272
pubmed: 34396188
Br J Cancer. 2013 Feb 19;108(3):691-8
pubmed: 23361055
Br J Cancer. 2007 May 7;96(9):1462-8
pubmed: 17406360
Lancet. 2011 Jan 8;377(9760):127-38
pubmed: 21183212
Gut. 2021 Jan;70(1):114-126
pubmed: 32482683
Circulation. 2018 Aug 14;138(7):735-742
pubmed: 30359132
Cancer Commun (Lond). 2021 Oct;41(10):1037-1048
pubmed: 34288593
Sci Rep. 2017 Oct 30;7(1):14300
pubmed: 29085026